• Home
  • Contributors
  • Glossary
  • Subscribe

Bioasis Technologies Inc.

The Science of Melanotransferrin (p97)

From the category archives:

Dr. Wilf Jefferies

New Early Diagnostic Test for Alzheimer’s Disease Developed in Japan

by Karen on April 28, 2010

biOasis Management and Advisory Team Growing; Information Now Available on S&P Market Access Program

by Christine on July 27, 2009

Seeking New Ways to Cross the Blood-Brain Barrier to Offer Better Treatments

by Christine on July 17, 2009

  • Pages

    • Contributors
    • Glossary
    • Robin (Rob) B. Hutchison, Chairman & CEO
  • Recent Posts

    • Sleep Disorder Predicts Dementia?
    • Controversy-plagued Genzyme Refuses Sanofi Acquisition
    • Mental Exercises Affect Alzheimer’s Disease
    • Blood-Brain Barrier Carriers – the Next Frontier for CNS Diseases?
    • What If Amyloid Actually Protected The Brain?
  • Categories

    • ADDL (1)
    • age-related neurodegenerative disease (150)
    • Alzheimer's Research (194)
    • amyloid beta deposits/plaques (64)
    • amyloid protein vaccination (4)
    • antidepressants (4)
    • axon deterioration (53)
    • BioAsis (106)
    • biosecurity (1)
    • biosimilar therapies (23)
    • biotechnology (151)
    • bioterrorism (1)
    • Blood Brain Barrier (53)
    • CEO (2)
    • cholinergic effects (1)
    • chronic neurological diseases (81)
    • Citizen Petition (4)
    • dementia (71)
    • diabetes (5)
    • DNA (5)
    • Dr. Wilf Jefferies (3)
    • FDA (14)
    • Frontotemporal Dementia (19)
    • Genentech (9)
    • Health reform (17)
    • Huntington's Disease (11)
    • Huntington’s Disease (5)
    • immunotherapy (1)
    • LDT (1)
    • Lewy Body Variant (5)
    • Melanotransferrin (64)
    • mental illness (51)
    • MOCA (2)
    • Neurological Diseases (163)
    • neurological disorders (68)
    • New Studies (18)
    • Not-for-Profit Organisations (9)
    • P97 (81)
    • Parkinson's (22)
    • Parkinson's Disease (32)
    • Parkinson’s (8)
    • personalized medicine (7)
    • Pfizer (36)
    • Pharma (31)
    • prescription medicine (13)
    • research cutbacks (31)
    • Research tools (4)
    • SEB (2)
    • Subsequent Entry Biologics (2)
    • tau tangles (30)
    • team members (3)
    • Uncategorized (29)
    • Unconventional treatments (4)
    • Vascular Dementia (23)
    • Wyeth (21)
  • Recent Comments

    • Blood-Brain Barrier Carriers - the Next Frontier for CNS Diseases? on The Blood-Brain Barrier: A Major Hurdle For Neurological Drug Delivery
    • What If Amyloid Actually Protected the Brain? on Will Anti-Amyloid Failures Change Pharma Approach?
    • Will Anti-Amyloid Failures Failures Change Pharma Approach? on Bapineuzumab’s Phase II Results Published – AD Drug Fails Expectations
    • Willa Zavala on Be Careful of Some Home Remedies for Alzheimer’s Disease
    • Biomarker Tests Can Revolutionize Alzheimer's Diagnosis and Treatment on biOasis CEO Rob Hutchison provides shareholder update
  • Archives

    • September 2010 (5)
    • August 2010 (17)
    • July 2010 (19)
    • June 2010 (18)
    • May 2010 (16)
    • April 2010 (17)
    • March 2010 (17)
    • February 2010 (15)
    • January 2010 (15)
    • December 2009 (16)
    • November 2009 (16)
    • October 2009 (17)
    • September 2009 (18)
    • August 2009 (18)
    • July 2009 (18)
    • June 2009 (15)
    • May 2009 (13)
    • April 2009 (13)
    • March 2009 (10)
    • February 2009 (16)
    • January 2009 (4)
    • September 2008 (1)
  • Categories

    • ADDL
    • age-related neurodegenerative disease
    • Alzheimer's Research
    • amyloid beta deposits/plaques
    • amyloid protein vaccination
    • antidepressants
    • axon deterioration
    • BioAsis
    • biosecurity
    • biosimilar therapies
    • biotechnology
    • bioterrorism
    • Blood Brain Barrier
    • CEO
    • cholinergic effects
    • chronic neurological diseases
    • Citizen Petition
    • dementia
    • diabetes
    • DNA
    • Dr. Wilf Jefferies
    • FDA
    • Frontotemporal Dementia
    • Genentech
    • Health reform
    • Huntington's Disease
    • Huntington’s Disease
    • immunotherapy
    • LDT
    • Lewy Body Variant
    • Melanotransferrin
    • mental illness
    • MOCA
    • Neurological Diseases
    • neurological disorders
    • New Studies
    • Not-for-Profit Organisations
    • P97
    • Parkinson's
    • Parkinson's Disease
    • Parkinson’s
    • personalized medicine
    • Pfizer
    • Pharma
    • prescription medicine
    • research cutbacks
    • Research tools
    • SEB
    • Subsequent Entry Biologics
    • tau tangles
    • team members
    • Uncategorized
    • Unconventional treatments
    • Vascular Dementia
    • Wyeth

Get smart with the Thesis WordPress Theme from DIYthemes.

WordPress Admin